Market Overview

UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs

Share:
Related BMY
Analyst's Key Takeaways From Eli Lilly, Bristol-Myer Squibb's Latest Conference Calls
Bristol-Myers Squibb Posts Upbeat Q2 Results, Lifts Profit Forecast
FDA accepts Merck's NDA for HCV combo grazoprevir/elbasvir (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Equal-Weight to Overweight, and raised the price target from $45.00 to $60.00.

In the report, Morgan Stanley noted, “Upgrading to OW and raising PT from $45 to $60 after raising 2020E EPS by 27%; $60 PT is up 23% from Friday's close. BMY is the leading contender to transform cancer treatment with new drugs that boost the immune system.”

Bristol-Myers Squibb Co. closed on Friday at $48.77.

Latest Ratings for BMY

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jul 2015JefferiesMaintainsHold
Jun 2015Piper JaffrayInitiates Coverage onUnderperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BMY)

Get Benzinga's Newsletters